ALG8 Inhibitors
ALG8 inhibitors include a diverse group of compounds that primarily target the glycosylation pathway. Tunicamycin is a well-known inhibitor of N-linked glycosylation, and by blocking the initial stages of glycoprotein synthesis, it effectively inhibits the functional activity of ALG8, which is responsible for adding glucose units to the dolichol-linked oligosaccharide precursor. Similarly, Swainsonine and Castanospermine target the glycoprotein processing in the Golgi apparatus, leading to misprocessed glycoproteins that can indirectly result in the functional inhibition of ALG8 due to the enzyme's role in the glycosylation pathway. Brefeldin A disrupts protein transport between the endoplasmic reticulum (ER) and Golgi, indirectly inhibiting ALG8 by impeding the normal trafficking and processing of glycoproteins, which is crucial for ALG8's role in the addition of glucose residues. Deoxynojirimycin and its analogs, such as deoxymannojirimycin and 1-deoxymannojirimycin, function as competitive inhibitors of various glycosidases. These compounds indirectly inhibit ALG8 by preventing the normal processing and maturation of N-linked glycans, which is a prerequisite for the proper function of ALG8 in glycoprotein synthesis.
Kifunensine, an inhibitor of mannosidase, can cause the accumulation of high-mannose glycans, which in turn can indirectly inhibit ALG8 by altering the glycosylation pathway and consequently affecting the enzyme's ability to add glucose residues properly. NB-DNJ (Miglustat) and its prodrug Celgosivir interfere with glycosidases and glucosylceramide synthase, respectively, leading to changes in the glycosylation patterns of proteins and lipids that can have a downstream effect on ALG8 activity. Salicylaldehyde's ability to modify amino groups on glycoproteins might lead to an accumulation of proteins with altered glycosylation within the ER, which can disrupt the proper function of ALG8 by causing a backlog in the glycosylation pathway.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Nucleoside antibiotic that inhibits N-linked glycosylation by blocking the transfer of N-acetylglucosamine to dolichol phosphate. ALG8 functions in the glycosylation pathway by adding glucose to the lipid-linked oligosaccharide precursor; inhibition by tunicamycin would prevent ALG8 from performing this function. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Indolizidine alkaloid that inhibits mannosidase II, affecting glycoprotein processing in the Golgi apparatus. This can lead to the accumulation of misprocessed glycoproteins, indirectly affecting the function of ALG8 by disrupting the glycosylation pathway. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Fungal metabolite that inhibits protein transport between the endoplasmic reticulum and Golgi apparatus. Since ALG8 operates in this pathway, the action of Brefeldin A can indirectly inhibit the function of ALG8 by disrupting the normal trafficking of glycoproteins. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
An indolizidine alkaloid that inhibits glucosidases I and II, which are involved in the trimming of glucose residues in N-glycan maturation. The inhibition of these enzymes can indirectly affect ALG8 function by causing improper glycoprotein folding and maturation. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Iminosugar that acts as a competitive inhibitor of several glycosidases, including those involved in the modification of N-linked glycans. By inhibiting these enzymes, deoxynojirimycin can indirectly inhibit ALG8 activity by disrupting the normal glycosylation process. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Analog of deoxynojirimycin that specifically inhibits α-mannosidases involved in glycan processing. Indirectly, this can inhibit ALG8 by preventing proper glycan maturation, which is necessary for ALG8's glycosylation function. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Mannosidase inhibitor that prevents the trimming of mannose residues in N-linked glycan maturation. This can lead to glycoprotein misprocessing, indirectly affecting the function of ALG8 by disrupting normal glycosylation. | ||||||
N-Butyldeoxynojirimycin·HCl | 210110-90-0 | sc-201398 sc-201398A sc-201398B | 5 mg 25 mg 50 mg | $180.00 $550.00 $985.00 | 4 | |
Iminosugar that inhibits glucosylceramide synthase and other glycosidases, affecting glycolipid metabolism and glycoprotein processing. This could indirectly inhibit ALG8 by altering the glycosylation patterns of proteins, impacting ALG8's glycosyltransferase function. | ||||||
Celgosivir | 121104-96-9 | sc-488385 sc-488385A sc-488385B | 5 mg 25 mg 100 mg | $525.00 $902.00 $2700.00 | ||
Prodrug of the iminosugar castanospermine and acts as an inhibitor of glucosidases. Celgosivir can indirectly inhibit ALG8 by disrupting the proper folding and processing of N-linked glycoproteins, impacting normal glycosylation. | ||||||